Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study

American Journal of Gastroenterology

Volumn 111, Issue 9, 2016, Pages 1297-1304

  Ahn, Joseph ^a   Lim, Joseph K ^b   Lee, Hannah M ^c   Lok, Anna S ^d   Nguyen, Mindie ^e   Pan, Calvin Q ^f   Mannalithara, Ajitha ^e   Te, Helen ^g   Reddy, K Rajender ^h   Trinh, Huy ⁱ   Chu, Danny ^j   Tran, Tram ^k   Lau, Daryl ^l   Leduc, Truong Sinh ^m   Min, Albert ⁿ   Trong Le, Loc ^o   Bae, Ho ^p   Van Tran, Sang ^q   Do, Son ^r   Hann, Hie Won L ^s   Wong, Clifford ^q   Han, Steven ^t   Pillai, Anjana ^u   Park, James S ^f   Tong, Myron ^u   Scaglione, Steve ^v   Woog, Jocelyn ^w   Kim, W Ray ^e   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e STANFORD UNIVERSITY   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ San Jose University   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^m Leduc Medical Group   (United States)

ⁿ BETH ISRAEL MEDICAL CENTER   (United States)

^o Woodholme Gastroenterology Asso   (United States)

^p Asian Pacific Liver Center   (United States)

^q Falls Church Family Practice ^*  (United States)

^r Digestive Health Associates of Texas   (United States)

^s THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u EMORY UNIVERSITY   (United States)

^v LOYOLA UNIVERSITY CHICAGO   (United States)

^w Asian Health Foundation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; ANTIVIRUS AGENT; GUANINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASIAN; CANCER INCIDENCE; CHRONIC HEPATITIS B; COHORT ANALYSIS; DISEASE REGISTRY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY ANALYSIS; STANDARDIZED INCIDENCE RATIO; UNITED STATES; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84975230726     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.257     Document Type: Article

References (25)

1. WHO. Fact Sheet No. 204 on Hepatitis B. Updated July 2015. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (last accessed on 16 February 2016).
2. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
3. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
4. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-52.
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
6. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
7. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-8.
8. Wong VW, Chan SL, Mo F et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-5.
9. Yang HI, Sherman M, Su J et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28: 2437-44.
10. Yang HI, Yuen MF, Chan HL et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-74.
11. Ahn J, Lee HM, Lim JK et al. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US-the ENUMERATE study. Aliment Pharmacol Ther 2015; 43: 134-44.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
13. Papatheodoridis G, Dalekos G, Sypsa V et al. PAGE-B: a risk score for hepatocellular carcinoma in Caucasians with chronic hepatitis B under a 5-year entecavir or tenofovir therapy. J Hepatol 2016; 64: 800-6.
14. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
15. Papatheodoridis GV, Chan HL, Hansen BE et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-67.
16. Zoutendijk R, Reijnders JG, Zoulim F et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760-5.
17. Yang SC, Lee CM, Hu TH et al. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother 2013; 68: 2154-63.
18. Hosaka T, Suzuki F, Kobayashi M et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
19. Wong GL, Chan HL, Mak CW et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-47.
20. Wu CY, Lin JT, Ho HJ et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014; 147: 143-51.
21. Gordon SC, Lamerato LE, Rupp LB et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014; 12: 885-93.
22. Kim WR, Loomba R, Berg T et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 2015; 121: 3631-8.
23. Coffin CS, Rezaeeaval M, Pang JX et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther 2014; 40: 1262-9.
24. Papatheodoridis GV, Dalekos GN, Yurdaydin C et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2015; 62: 363-70.
25. Arends P, Sonneveld MJ, Zoutendijk R et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2015; 64: 1289-95.